July 2019—Natera announced plans to commercialize a research-use-only service for whole exome sequencing of circulating tumor DNA using plasma samples from patients with cancer.
Read More »Natera collaborates with Fox Chase
October 2018—Natera announced it has partnered with Fox Chase Cancer Center to assess the Signatera (RUO) ctDNA assay for recurrence monitoring of kidney cancer.
Read More »Natera, Institut Jules Bordet collaborate
August 2018—Natera announced a research collaboration with the Institut Jules Bordet, in Brussels, using the company’s Signatera research-use-only circulating tumor DNA assay to evaluate molecular response and minimal residual disease in women with early stage breast cancer.
Read More »Qiagen, Natera to develop genetic testing assays, 5/18
May 2018—Qiagen and Natera will partner to develop cell-free DNA assays, including for prenatal screening, for use on the Qiagen GeneReader NGS System.
Read More »Natera selected for ctDNA study, 12/17
December 2017—Natera announced a second research collaboration with Denmark’s Aarhus University utilizing the company’s research use only technology to evaluate ctDNA as a useful biomarker for detecting minimal residual disease, treatment response, and disease recurrence in colorectal cancer patients. (The university will also use the Signatera technology in a bladder cancer study.)
Read More »NIPT for screening twin pregnancies, 11/17
November 2017—Natera announced that its Panorama noninvasive prenatal test is validated to screen twin pregnancies for zygosity and chromosomal abnormalities. Panorama can tell the difference between the mother’s and the baby’s DNA, enabling it to distinguish between each twin’s DNA.
Read More »Natera to continue using Illumina’s HiSeq 2500, 10/13
Illumina and Natera announced they have entered into a three-year agreement whereby Illumina will supply Natera with the HiSeq 2500 sequencing system and associated consumables for performing Natera’s noninvasive prenatal test (NIPT) Panorama.
Read More »